Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss

Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line

(2013) Ling Wang et al.   Cancer Cell International

Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals

(2013) Abdel-Moneim M Osman et al.   Cancer Cell International

Celastrol induces apoptosis of gastric cancer cells by miR-146a inhibition of NF-κB activity

(2013) Min Sha et al.   Cancer Cell International

Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells

(2012) Kuen-Feng Chen et al.   BIOCHEMICAL PHARMACOLOGY

Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line

(2012) Abdel-Moneim M Osman et al.   Cancer Cell International

Synergistic Effects of Combination Treatment with Bortezomib and Doxorubicin in Human Neuroblastoma Cell Lines

(2012) Bo-Yu Du et al.   CHEMOTHERAPY

NF-κB and the link between inflammation and cancer

(2012) Joseph A. DiDonato et al.   IMMUNOLOGICAL REVIEWS

Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

(2012) Alfeu Zanotto-Filho et al.   INVESTIGATIONAL NEW DRUGS

α2β1 Integrin Promotes Chemoresistance against Doxorubicin in Cancer Cells through Extracellular Signal-regulated Kinase (ERK)

(2012) Dalila Naci et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo

(2012) Yong-Wei Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

(2012) Steven E. Lipshultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells

(2012) Alexander Aranovich et al.   MOLECULAR CELL

Cross-Talk between NFkB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis

(2012) Azhar R. Hussain et al.   PLoS One

Hypoxia suppresses conversion from proliferative arrest to cellular senescence

(2012) O. V. Leontieva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia

(2012) Jing Liu et al.   ACS Medicinal Chemistry Letters

Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1

(2012) Bray Denard et al.   eLife

Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells

(2011) W. Zhang et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer Model

(2011) Lili Bao et al.   AMERICAN JOURNAL OF PATHOLOGY

Proteasome inhibitor MG132-induced apoptosis via ER stress-mediated apoptotic pathway and its potentiation by protein tyrosine kinase p56lck in human Jurkat T cells

(2011) Hae Sun Park et al.   BIOCHEMICAL PHARMACOLOGY

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas

(2011) Dharminder Chauhan et al.   BMC BIOLOGY

Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence

(2011) Georgina Hernandez-Flores et al.   BMC CANCER

Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells

(2011) Radhamani Kannaiyan et al.   BRITISH JOURNAL OF PHARMACOLOGY

3,5-Dimethyl-7H-Furo[3,2-g]Chromen-7-One as a Potential Anticancer Drug by Inducing p53-Dependent Apoptosis in Human Hepatoma HepG2 Cells

(2011) Jian-guo Sun et al.   CHEMOTHERAPY

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Curcumin Enhances the Efficacy of Chemotherapy by Tailoring p65NFκB-p300 Cross-talk in Favor of p53-p300 in Breast Cancer

(2011) Gouri Sankar Sen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Four faces of cellular senescence

(2011) Francis Rodier et al.   JOURNAL OF CELL BIOLOGY

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

Correlation of NF-κB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma

(2010) Ming Yan et al.   BMC CANCER

The chemotherapeutic agent bortezomib induces the formation of stress granules

(2010) Marie-Josée Fournier et al.   Cancer Cell International

Epidemiology of childhood cancer

(2010) Peter Kaatsch   CANCER TREATMENT REVIEWS

Molecular Pathways Linking Inflammation and Cancer

(2010) A. Mantovani   CURRENT MOLECULAR MEDICINE

The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention

(2010) Di Chen et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

Therapy-Induced Senescence in Cancer

(2010) Jonathan A. Ewald et al.   JNCI-Journal of the National Cancer Institute

Targeting mitochondria for cancer therapy

(2010) Simone Fulda et al.   NATURE REVIEWS DRUG DISCOVERY

Significance of Cellular Senescence in Aging and Cancer

(2010) Angela Grimes et al.   Cancer Research and Treatment

Cellular Senescence and Inflammation: A Noteworthy Link

(2009) George Tsirpanlis   BLOOD PURIFICATION

The pharmacological NFκB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation

(2009) Alfeu Zanotto-Filho et al.   CANCER LETTERS

Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin – An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity

(2009) Ilona Steppan et al.   CHEMOTHERAPY

Cellular Senescence in the Development and Treatment of Cancer

(2009) Gabriele Saretzki   CURRENT PHARMACEUTICAL DESIGN

A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome

(2008) Jinbao Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation

(2008) David A. Gewirtz et al.   BIOCHEMICAL PHARMACOLOGY

Bcl-2-family proteins and hematologic malignancies: history and future prospects

(2008) J. C. Reed   BLOOD

Nuclear Factor-κB Activation: From Bench to Bedside

(2008) Gautam Sethi et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Mitochondrial dynamics and apoptosis

(2008) D.-F. Suen et al.   GENES & DEVELOPMENT

MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-κB and activator protein-1

(2008) Pablo C. Ortiz-Lazareno et al.   IMMUNOLOGY

Mitochondria in cancer cells: what is so special about them?

(2008) Vladimir Gogvadze et al.   TRENDS IN CELL BIOLOGY